ILiAD Biotechnologies Announces Upcoming Presentation at the European Society for Paediatric Infectious Diseases 2020 Virtual Meeting
October 21, 2020 08:00 ET
|
ILiAD Biotechnologies
WESTON, Fla., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a company utilizing proprietary B-Tech technology to develop next generation infectious disease vaccines, today...
ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1
September 29, 2020 17:00 ET
|
ILiAD Biotechnologies
-- Phase 2b study in healthy volunteers met primary endpoints of overall safety and induction of mucosal immunity ---- BPZE1 prevented colonization from re-vaccination/challenge in 90% of subjects...
ILiAD Biotechnologies Announces Presentation of Positive Phase 2b Data for Next Generation Pertussis Vaccine at World Vaccine Congress
September 24, 2020 08:00 ET
|
ILiAD Biotechnologies
WESTON, Fla., Sept. 24, 2020 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a company utilizing proprietary B-Tech technology to develop next generation infectious disease vaccines, today...